These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29439357)

  • 1. Dale Schenk One Year Anniversary: Fighting to Preserve the Memories.
    Overk C; Masliah E
    J Alzheimers Dis; 2018; 62(1):1-13. PubMed ID: 29439357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.
    Valera E; Masliah E
    Pharmacol Ther; 2013 Jun; 138(3):311-22. PubMed ID: 23384597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 20th Anniversary of Neurodegenerative Diseases: A Parallel (R)Evolution between the 20th and the 21st Century?
    Allali G
    Neurodegener Dis; 2024; 24(1):2-5. PubMed ID: 38776877
    [No Abstract]   [Full Text] [Related]  

  • 4. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
    Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
    Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFFITOME® technology in neurodegenerative diseases: the doubling advantage.
    Schneeberger A; Mandler M; Mattner F; Schmidt W
    Hum Vaccin; 2010 Nov; 6(11):948-52. PubMed ID: 20980801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.
    Overk CR; Rockenstein E; Florio J; Cheng Q; Masliah E
    Neuroscience; 2015 Dec; 310():549-60. PubMed ID: 26341908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. John Hardy is the UK's first Breakthrough Prize laureate.
    Martin SJ
    FEBS J; 2015 Dec; 282(24):4641-2. PubMed ID: 26573785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials.
    Nimmo JT; Kelly L; Verma A; Carare RO; Nicoll JAR; Dodart JC
    Front Neurosci; 2021; 15():733857. PubMed ID: 34539340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special Issue "Commemorative Issue Celebrating the 20th Anniversary of the Alzheimer's Foundation of America: Understanding and Treating Alzheimer's Disease".
    Reiss AB; Pinkhasov A
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
    Kanemaru K
    Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
    Kumar P; Pradhan K; Karunya R; Ambasta RK; Querfurth HW
    J Neurochem; 2012 Feb; 120(3):350-70. PubMed ID: 22098618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.
    Arevalo-Villalobos JI; Rosales-Mendoza S; Zarazua S
    Expert Rev Vaccines; 2017 Feb; 16(2):151-159. PubMed ID: 27579524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
    Kayed R; Jackson GR
    Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.
    Fu L; Li Y; Hu Y; Zheng Y; Yu B; Zhang H; Wu J; Wu H; Yu X; Kong W
    Sci Rep; 2017 Jan; 7():41041. PubMed ID: 28106117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.